Cas:864685-04-1 N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine manufacturer & supplier

We serve Chemical Name:N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine CAS:864685-04-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine

Chemical Name:N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine
CAS.NO:864685-04-1
Synonyms:(3,3-dimethoxy-propyl)-(4-methyl-pyridin-2-yl)-amine
Molecular Formula:C11H18N2O2
Molecular Weight:210.27300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:43.38000
Exact Mass:210.13700
LogP:1.88390

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (3,3-dimethoxy-propyl)-(4-methyl-pyridin-2-yl)-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(3,3-dimethoxy-propyl)-(4-methyl-pyridin-2-yl)-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3,3-dimethoxy-propyl)-(4-methyl-pyridin-2-yl)-amine Use and application,(3,3-dimethoxy-propyl)-(4-methyl-pyridin-2-yl)-amine technical grade,usp/ep/jp grade.


Related News: Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine manufacturer The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine supplier Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine vendor Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. N-(3,3-dimethoxypropyl)-4-methylpyridin-2-amine factory Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.